Geron Corporation (GERN – Analyst Report) was in the spotlight last week with the company striking a collaboration deal with Johnson & Johnson for its sole pipeline candidate, imetelstat. Meanwhile, companies like Gilead (GILD – Analyst Report) and Regeneron (REGN – Analyst Report) remained in the news thanks to regulatory updates.Recap of the Week’s Most Important Stories1. Geron, which had […]
View gallery.With the help of an almost vertical rise in the overall stock market, most industries within the market have also performed very well. As they say, “a rising tide raises all ships.”Some industries, however, have performed better than others. For example, airlines and railroads have been the two top-performing industries, while gold miners have been the worst.Another industry that’s […]
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and rough trading in between. Encouraging industry trends, increasing merger and acquisition activities, expansion into emerging markets and ever-increasing health care spending led the sector to easily outperform the broader U.S. equity markets.Though lofty valuations and regulatory concerns did bring in some pain […]
By Ben LevisohnYes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:
October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the S&P 500 in 14 out the last 20 years. We believe […]
Which biotech stock has been picking up the most steam as of late?First, let’s define “as of late.” After all, different time horizons would result in different leaders and laggards. And traders and investors would be looking for different things.Traders might be looking for stocks that are accelerating only in the short term, while investors might be longer for the […]
SummaryWith the stock trading at a P/E of 9, these shares are still cheap.
Pfizer is trading at a P/E that is almost 30 points below Merck (MRK), 13 points below Novartis (NVS) and 15 point below Sanofi (SNY).
At around $30 per share, investors that are looking for exposure in the health care industry and values 3.5% dividend yield should not […]
GoGrowth Stocks Showed Weakness On Above Average TradePosted by: : Paul EbelingPosted on: July 16, 2014GoGrowth Stocks Showed Weakness On Above Average TradeIBB, GS, JPM, LO, RAI, FB, MCO, TWTR, YELP, JBHTDJIA +2.9% YTD , S&P 500 +6.8% YTD, NAS 100 +5.7% YTD , Russell 2000 -0.8% YTDDJIA +5.26 at 17060.68, NAS 100 -24.03 at 4416.39, S&P 100 -3.82 at 1973.28Volume: trade was above average at 716-M/shrs changing hands on the […]
By Larry DarrellPublished: July 15, 2014 at 3:25 pm ESTClick Ticker to See live coverageSOCL
NDX
FB
TSLA
TWTR
IBB
Social media and biotechnology stocks have been under scrutiny for their high valuations, raising concerns among many investors as well as the US Federal Reserve. In the Fed’s biannual report on monetary policy, the central bank voiced concerns over these so-called momentum stocks.“Nevertheless, valuation metrics in […]
Sometimes an “up” day isn’t just any “up” day.
Not only did the stock market push higher yesterday, the S&P made a very specific, positive move in the form of a break through its 3-year channel resistance. This should lead to an increase in prices for the S&P, at least in the short-run.
Well, thanks to the market’s move higher, several stocks […]
It isn’t a surprise to most that the biotech names have had a rough start to the year.
Really, March was pretty bad.
However, with the market recovering as of late, many of the beaten up biotech stocks have rebounded somewhat. A lot of analysts believe the rebound will continue.
As an investor, if you agree with those analysts, then it certainly wouldn’t […]
